XTalks

FEBRUARY 27, 2024

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Roots Analysis

JANUARY 28, 2024

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

Big Data 40

Big Data Medicine Marketing Clinical Trials 40

Drug Discovery World

OCTOBER 3, 2022

She also works on her own research following her PhD in the digitisation of scientific research, smart labs and the lab of the future, and semantic tagging of scientific data, which she has continued as part of the Physical Sciences Data Infrastructure (PSDI) Project. Fellowship Programme.

Drugs 52

Drugs Scientist Bioinformatics Medicine 52

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

XTalks

JANUARY 19, 2024

In 2023, there have been pivotal trends shaping the landscape and application of alpha emitter therapy. The discussion centered on the evolving potential of alpha particle therapy for treating advanced and metastatic tumors. There have been a number of advancements common to both external beam and radiopharmaceutical therapy.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 13, 2023

Jannick Bendtsen, CEO, PipeBio, on: ‘Accelerating antibody development: Advancing discovery through integrated bioinformatics and machine learning’. He will discuss selection technologies for membrane targets using advances in whole cell panning and comparative deep sequencing.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

OCTOBER 21, 2022

Accordingly, advances in flow cytometry technology – both in instrumentation and reagent offerings – are enabling researchers to decipher these questions, leading to new discoveries and diagnostic tools. . However, despite impressive advances in modern flow cytometry, many bottlenecks remain that require constant research and investment.

Reagent 52

Reagent Antibody Drugs Protein 52